Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection: The BEYOND Double-Blind Randomized Clinical Trial

NCT05304715 is registered in ClinicalTrials.gov with Hellenic Institute for the Study of Sepsis as lead sponsor.

NCT NCT05304715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection: The BEYOND Double-Blind Randomized Clinical Trial
Lead sponsor
Hellenic Institute for the Study of Sepsis
Phase
Phase 2
Overall status
Completed
Start date
April 13, 2022
Completion date
June 4, 2023
Enrollment
44 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

clostridioides difficile infection, clostridioides difficile infection recurrence, mortality, organ dysfunction syndrome, stool microbiome